OncoMatch/Bile Duct Cancer (Cholangiocarcinoma)/IDH2

Bile Duct Cancer (Cholangiocarcinoma)IDH2 Clinical Trials

IDH2 mutations occur in approximately 5% of cholangiocarcinoma, less frequently than IDH1, and produce 2-hydroxyglutarate through the same neomorphic mechanism. Enasidenib (an IDH2 inhibitor) and pan-IDH inhibitors covering both variants have been studied in biliary tract cancers. Trials evaluate selective IDH2 inhibitors and combination approaches in IDH2-mutant cholangiocarcinoma alongside IDH1-mutant cohorts.